Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens

Counoupas, Claudio; Pino, Paco; Stella, Alberto Ospina; Ashley, Caroline L; Lukeman, Hannah; Bhattacharyya, Nayan D.; Tada, Takuya; Anchisi, Stéphanie; Metayer, Charles; Martinis, Jacopo; Aggarwal, Anupriya; Dcosta, Belinda M; Kint, Joeri; Wurm, Maria J; Landau, Nathaniel R.; Steain, Megan; Turville, Stuart; Wurm, Florian Μ.; David, Sunil A.; Triccas, James A.

doi:10.1101/2021.08.18.456891

Cited by 2 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quantitation of nAb titres using a pseudovirus assay nAbs were quantitated against replication-deficient SARS-CoV-2 ancestral (Wuhan) Spike pseudotyped lentivirus particles as previously described 60 . Briefly, pseudovirus particles were generated by co-transfecting a Spike expression construct pCG1-SARS-2-S Δ18 61,62 and GFP-luciferase vector with lentivirus packaging and helper plasmids into HEK293T cells, using Fugene HD (Promega) 63 .…”

Section: Cell Lines For Infection Assaysmentioning

confidence: 99%

Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

et al. 2022

View full text Add to dashboard Cite

Current vaccines against SARS-CoV-2 substantially reduce mortality, but protection against infection is less effective. Enhancing immunity in the respiratory tract, via mucosal vaccination, may provide protection against infection and minimise viral spread. Here, we report testing of a subunit vaccine in mice, consisting of SARS-CoV-2 Spike protein with a TLR2-stimulating adjuvant (Pam2Cys), delivered to mice parenterally or mucosally. Both routes of vaccination induce substantial neutralising antibody (nAb) titres, however, mucosal vaccination uniquely generates anti-Spike IgA, increases nAb in the serum and airways, and increases lung CD4+ T-cell responses. TLR2 is expressed by respiratory epithelia and immune cells. Using TLR2 deficient chimeric mice, we determine that TLR2 expression in either compartment facilitates early innate responses to mucosal vaccination. By contrast, TLR2 on hematopoietic cells is essential for optimal lung-localised, antigen-specific responses. In K18-hACE2 mice, vaccination provides complete protection against disease and sterilising lung immunity against SARS-CoV-2, with a short-term non-specific protective effect from mucosal Pam2Cys alone. These data support mucosal vaccination as a strategy to improve protection in the respiratory tract against SARS-CoV-2 and other respiratory viruses.

show abstract

Section: Cell Lines For Infection Assaysmentioning

confidence: 99%

Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Quantitation of nAb titres using a pseudovirus assay nAbs were quantitated against replication-de cient SARS-CoV-2 ancestral (Wuhan) Spike pseudotyped lentivirus particles as previously described 59 . Brie y, pseudovirus particles were generated by cotransfecting a Spike expression construct pCG1-SARS-2-S Δ18 60,61 and GFP-luciferase vector with lentivirus packaging and helper plasmids into HEK293T cells, using Fugene HD (Promega) 62 .…”

Section: Quantitation Of Anti-spike Igg and Igamentioning

confidence: 99%

Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

Ashhurst

Johansen

Maxwell

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Current vaccines against SARS-CoV-2 substantially reduce mortality, but protection against infection is less effective. Enhancing immunity in the respiratory tract, via mucosal vaccination, may provide protection against infection and minimise viral spread. We tested a novel subunit vaccine in mice, consisting of SARS-CoV-2 Spike protein with a TLR2-stimulating adjuvant, delivered to mice parenterally or mucosally. Both routes of vaccination induced substantial neutralising antibody (nAb) titres, however, mucosal vaccination uniquely generated anti-Spike IgA, increased nAb in the serum and airways, and increased lung CD4+ T-cell responses. TLR2 is expressed by respiratory epithelia and immune cells. Using TLR2 deficient chimeric mice, we determined that TLR2 expression in either compartment facilitated early innate responses to mucosal vaccination. By contrast, TLR2 on hematopoietic cells was essential for optimal lung-localised, antigen-specific responses. In a K18-hACE2 mice, vaccination provided complete protection against disease and sterilising lung immunity against SARS-CoV-2. These data support mucosal vaccination as a strategy to improve protection in the respiratory tract against SARS-CoV-2 and other respiratory viruses.

show abstract

Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens

Cited by 2 publications

References 22 publications

Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice

Contact Info

Product

Resources

About